Association of lipoprotein-associated phospholipase A 2 with characteristics of vulnerable coronary atherosclerotic plaques

Yonsei Medical Journal

Volumn 52, Issue 6, 2011, Pages 914-922

  Liu, Yu Sheng ^a,b   Hu, Xiao Bo ^a   Li, Hong Zhuan ^c   Jiang, Wei Dong ^b   Wang, Xin ^b   Lin, Hao ^b   Qin, Ai Qiong ^b   Wang, Yong Mei ^b   Zhao, Tong ^b   Dong, Zhao Qiang ^b   Zhang, Mei ^a   Lu, Qing Hua ^b  

^a SHANDONG UNIVERSITY   (China)

^b THE SECOND HOSPITAL OF SHANDONG UNIVERSITY   (China)

^c SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

Atherosclerosis; Lipoprotein associated phospholipase A 2; Vulnerable plaque

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; FEMALE; FOLLOW UP; HUMAN; INTRAVASCULAR ULTRASOUND; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; STABLE ANGINA PECTORIS; UNSTABLE ANGINA PECTORIS;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADULT; AGED; AGED, 80 AND OVER; ANGINA, STABLE; ANGINA, UNSTABLE; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 80054982473     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2011.52.6.914     Document Type: Article

References (21)

1. Barth J, Schumacher M, Herrmann-Lingen C. Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis. Psychosom Med 2004;66:802-13.
2. Genest J. C-reactive protein: risk factor, biomarker and/or therapeutic target? Can J Cardiol 2010;26 Suppl A:41A-4A.
3. Packard CJ, O'Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 2000;343:1148-55.
4. Lp-PLA(2) Studies Collaboration, Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010;375: 1536-44.
5. Tellis CC, Tselepis AD. The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochim Biophys Acta 2009;1791:327-38.
6. Asano K, Okamoto S, Fukunaga K, Shiomi T, Mori T, Iwata M, et al. Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma. Biochem Biophys Res Commun 1999;261: 511-4.
7. Stafforini DM, Elstad MR, McIntyre TM, Zimmerman GA, Prescott SM. Human macrophages secret platelet-activating factor acetylhydrolase. J Biol Chem 1990;265:9682-7.
8. Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 2005;25:923-31.
9. Häkkinen T, Luoma JS, Hiltunen MO, Macphee CH, Milliner KJ, Patel L, et al. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1999;19:2909-17.
10. Kolodgie FD, Burke AP, Skorija KS, Ladich E, Kutys R, Makuria AT, et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2006;26:2523-9.
11. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation 2003;108:1772-8.
12. Mintz GS, Nissen SE, Anderson WD, Bailey SR, Erbel R, Fitzgerald PJ, et al. American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2001;37: 1478-92.
13. Tang D, Yang C, Zheng J, Woodard PK, Saffitz JE, Petruccelli JD, et al. Local maximal stress hypothesis and computational plaque vulnerability index for atherosclerotic plaque assessment. Ann Biomed Eng 2005;33:1789-801.
14. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-95.
15. Anderson JL. Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention. Am J Cardiol 2008;101:23F-33F.
16. Reddy KJ, Singh M, Bangit JR, Batsell RR. The role of lipoprotein-associated phospholipase A2 on cardiovascular disease risk assessment and plaque rupture: a clinical review. J Clin Lipidol 2009;3:85-93.
17. Rosenson RS. Lp-PLA(2) and risk of atherosclerotic vascular disease. Lancet 2010;375:1498-500.
18. Brilakis ES, Khera A, McGuire DK, See R, Banerjee S, Murphy SA, et al. Influence of race and sex on lipoprotein-associated phospholipase A2 levels: observations from the Dallas Heart Study. Atherosclerosis 2008;199:110-5.
19. Virmani R, Burke AP, Kolodgie FD, Farb A. Pathology of the thin-cap fibroatheroma: a type of vulnerable plaque. J Interv Cardiol 2003;16:267-72.
20. Kashiwagi M, Tanaka A, Kitabata H, Tsujioka H, Matsumoto H, Arita Y, et al. Relationship between coronary arterial remodeling, fibrous cap thickness and high-sensitivity C-reactive protein levelsin patients with acute coronary syndrome. Circ J 2009;73:1291-5.
21. Schoenhagen P, Ziada KM, Kapadia SR, Crowe TD, Nissen SE, Tuzcu EM. Extent and direction of arterial remodeling in stable versus unstable coronary syndromes: an intravascular ultrasound study. Circulation 2000;101:598-603.